Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder

Bipolar Disorders

Volumn 14, Issue SUPPL.2, 2012, Pages 1-21

  Malhi, Gin S ^a,b   Bargh, Danielle M ^a,b   Mcintyre, Roger ^c,d,e   Gitlin, Michael ^f   Frye, Mark A ^g   Bauer, Michael ^h   Berk, Michael ^i,j,k,l,m  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁱ DEAKIN UNIVERSITY   (Australia)

^j THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l BARWON HEALTH   (Australia)

^m FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

more..

Author keywords

Acute treatment; Bipolar disorder; Evidence based review; Guidelines; Maintenance treatment; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; LAMOTRIGINE; LITHIUM; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ALCOHOL BLOOD LEVEL; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; BLOOD CELL COUNT; BLOOD PRESSURE; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOMANIA; LIVER FUNCTION; MAINTENANCE THERAPY; MIXED ANXIETY AND DEPRESSION; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE; REVIEW; SIDE EFFECT; SMOKING; SOMNOLENCE; SUICIDE; THYROID FUNCTION; TREATMENT RESPONSE; WEIGHT GAIN;

ACUTE DISEASE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84859829264     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.00989.x     Document Type: Review

References (150)

1. Judd LL, Akiskal HS, Schetteler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
2. Leboyer MK, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry 2010; 71: 1689-1695.
3. Merikangas KR, Jin R, He J-P et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry 2011; 68: 241-251.
4. Zimmerman M, Galione JN, Chelminski I, Young D, Dalrymple K, Ruggero CJ. Sustained unemployment in psychiatric outpatients with bipolar disorder: frequency and association with demographic variables and comorbid disorders. Bipolar Disord 2010; 12: 720-726.
5. Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry 1996; 39: 896-899.
6. Dalton EJ, Cate-Carter TD, Mundo E, Parikh SV, Kennedy JL. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 2003; 5: 58-61.
7. Leverich GS, Altshuler LL, Frye MA et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 2003; 64: 506-515.
8. Collins PY, Patel V, Joestl SS et al. Grand challenges in global mental health. Nature 2011; 475: 27-30.
9. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: Re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73: 123-131.
10. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
11. Perugi G, Micheli C, Akiskal HS et al. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr Psychiatry 2000; 41: 13-18.
12. Gao K, Kemp DE, Conroy C, Ganocy SJ, Findling RL, Calabrese JR. Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients. Int J Clin Pract 2010; 64: 336-344.
13. Matza LS, Rajagopalan KS, Thompson CL et al. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry 2005; 66: 1432-1440.
14. Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008; 69 (Suppl. 5): 9-15.
15. Malhi GS, Adams D. Are guidelines in need of CPR? The development of clinical practice recommendations (CPR). Acta Psychiatr Scand 2009; 119 (Suppl. 439): 5-7.
16. Ansari A, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. Harv Rev Psychiatry 2010; 18: 36-55.
17. Scott J. Psychotherapy for bipolar disorders - Efficacy and effectiveness. J Psychopharmacol 2006; 20: 46-50.
18. Correll CU. Individualizing treatment for patients with bipolar disorder: Optimizing efficacy, safety, and tolerability. Ann Clin Psychiatry 2011; 22: 49-81.
19. Malhi GS, Adams D, Berk M. The pharmacological treatment of bipolar disorder in primary care. Med J Aust 2010; 193 (Suppl. 4): 24-30.
20. Malhi GS, Adams D, Lampe L et al.. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand 2009; 119 (Suppl. 439): 27-46.
21. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004; 6: 504-518.
22. Berk L, Hallam KT, Colom F et al. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol 2010; 25: 1-16.
23. Semple D, Smyth R. Bipolar Illness Oxford Handbook of Psychiatry, 2nd ed. New York: Oxford University Press, 2009.
24. Nivoli AM, Colom F, Murru A et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011; 129: 14-26.
25. Malhi GS, Adams D, Cahill CM, Dodd S, Berk M. The management of individuals with bipolar disorder. Drugs 2009; 69: 2063-2101.
26. Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord 2009; 11: 55-76.
27. Berk M, Kapczinski F, Andreazza AC, Dean OM et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
28. McIntyre R, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord 2012; 14 (Suppl. 2): 22-36.
29. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord 2012; 14 (Suppl. 2): 37-50.
30. Gitlin M, Frye M. Maintenance therapies in bipolar disorders. Bipolar Disord 2012; 14 (Suppl. 2): 51-65.
31. Malhi GS, Chengappa KNR, Gershon S, Goldberg JF. Hypomania: hype or mania? Bipolar Disord 2010; 12: 758-763.
32. Judd LL, Akiskal HS, Schettler PJ et al. Psychosocial disability in the course of bipolar I and II disorders. Arch Gen Psychiatry 2005; 62: 1322-1330.
33. Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-121.
34. Keck PE, Orsulak PJ, Cutler AJ et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009; 112: 36-49.
35. Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57: 841-849.
36. McIntyre RS, Brecherb M, Paulssonc Br, Huizarc K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15: 573-585.
37. Nivoli AMA, Murru A, Vieta E. Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuropsychobiology 2010; 62: 27-35.
38. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442-455.
39. Sachs G, Chengappa KNR, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6: 213-223.
40. McIntyre RS, Konarski JZ, Jones M, Paulsson B. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 2007; 100 (Suppl. 1): 5-14.
41. Sussman N, Mullen J, Paulsson B, Vagero M. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. J Affect Disord 2007; 100 (Suppl. 1): 55-63.
42. Tohen M, Chengappa KNR, Suppes T, Zarate CA et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62-69.
43. Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003; CD004052.
44. Clark HM, Berk M, Shlomo B. A randomized controlled single blind study of the efficacy of clonazepam and lithium in the treatment of acute mania. Hum Psychopharm Clin 1997; 12: 325-328.
45. Weisler RH, Hirschfeld R, Cutler AJ et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006; 20: 219-231.
46. Oquendo MA, Waternaux C, Brodsky B et al. Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord 2000; 59: 107-117.
47. Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry 2005; 66: 693-704.
48. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W, Group BS. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9: 413-425.
49. Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600-609.
50. Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010; 124: 228-234.
51. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9.
52. Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360.
53. van der Loos MLM, Mulder P, Hartong EGTM, Blom MBJ, Vergouwen AC, van Noorden MS et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand 2010; 122: 246-254.
54. Ghaemi SN, Gilmer WS, Goldberg JF et al.. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 1840-1844.
55. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
56. van der Loos MLM, Mulder PG, Hartong EGTM et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223-231.
57. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 2005.
58. Dodd S, Kulkarni J, Berk L et al. A prospective study of the impact of subthreshold mixed states on the 24-month clinical outcomes of bipolar I disorder or schizoaffective disorder. J Affect Disord 2010; 124: 22-28.
59. Henry C, M'Bailara K, Desage A, Gard S, Misdrahi D, Vieta E. Towards a reconceptualization of mixed states, based on an emotional-reactivity dimensional model. J Affect Disord 2007; 101: 35-41.
60. Khalsa HMK, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J Affect Disord 2008; 106: 179-184.
61. Minnai GP, Tondo L, Salis P et al. Secular trends in first hospitalizations for major mood disorders with comorbid substance use. Int J Neuropsychopharmcol 2006; 9: 319-326.
62. Perugi G, Akiskal HS, Micheli C, Toni C, Madaro D. Clinical characterization of depressive mixed state in bipolar-I patients: Pisa-San Diego collaboration. J Affect Disord 2001; 67: 105-114.
63. Azorin J-M, Aubrun E, Bertsch J, Reed C, Gerard S, Lukasiewicz M. Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24months-European mania in bipolar longitudinal evaluation of medication. BMC Psychiatry 2009; 9: 33.
64. Valtonen HM, Suominen K, Haukka J et al. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord 2008; 10: 588-596.
65. Tohen M, Zarate CA, Jr., Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003; 160: 2099-107.
66. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008; 69 (Suppl. 1): 4-17.
67. Berk M, Ng F, Dodd S, Goldberg JF, Malhi GS. Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. Psychiatry Clin Neurosci 2010; 64: 367-371.
68. Vieta E, Nuamah IF, Lim P et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010; 12: 230-243.
69. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 229-234.
70. Bowden CL, Swann AC, Calabrese JR et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006; 67: 1501-1510.
71. Khazaal Y, Tapparel S, Chatton A, Rothen S, Preisig M, Zullino D. Quetiapine dosage in bipolar disorder episodes and mixed states. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 727-730.
72. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2009; 116: 43-50.
73. Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010; 24: 547-558.
74. Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-748.
75. Potkin SG, Keck PE, Jr., Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 301-310.
76. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11: 673-686.
77. Suppes T, Eudicone J, McQuade R, Pikalov A III, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008; 107: 145-154.
78. Perlis RH, Ostacher MJ, Miklowitz DJ et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry 2010; 71: 296-303.
79. Gaudiano BA, Weinstock LM, Miller IW. Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development. Behav Modif 2008; 32: 267-301.
80. Lauder SD, Berk M, Castle DJ, Dodd S, Berk L. The role of psychotherapy in bipolar disorder. Med J Aust 2010; 193 (Suppl. 4): 31-35.
81. Miklowitz DJ, Otto MW, Frank E et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch of Gen Psychiatry 2007; 64: 419-426.
82. Castle D, White C, Chamberlain J, Berk M, Berk L, Lauder S et al. Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry 2010; 196: 383-388.
83. Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2010; 123: 175-189.
84. Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009; 119: 22-27.
85. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
86. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.
87. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483-493.
88. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222.
89. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489.
90. Geddes JR, Goodwin GM, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-395.
91. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290.
92. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256.
93. Keck PE, Jr., Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-637.
94. Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13: 133-144.
95. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: A randomized controlled study). J Clin Psychiatry 2011; 72: 1452-1464.
96. Vieta E, Cruz N, Garcia-Campayo J et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmcol 2008; 11: 445-452.
97. Suppes T, Vieta E. Maintenance treatment for patients with bipolar I disorder: Results from a North American study of quetiapine in combination with lithium or divalproex. Am J Psychiatry 2009; 166: 1186-1187.
98. van der Loos MLM, Mulder P, Hartong EGTM et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord 2011; 13: 111-117.
99. Berk M, Brnabic A, Dodd S et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011; 13: 87-98.
100. Malhi GS, Bargh DM, Cashman E, Frye M, Gitlin M. The clinical management of bipolar disorder complexity using a stratified model. Bipolar Disord 2012; 14 (Suppl. 2): 66-89.
101. Macneil CA, Hasty MK, Berk M et al. Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Early Interv Psychiatry 2011; 5: 100-107.
102. Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry 2007; 20: 17-22.
103. Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann NY Acad Sci 2001; 932: 24-43.
104. Muller-Oerlinghausen B, Berghofer A, Ahrens B. The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 2003; 48: 433-439.
105. Yatham LN, Kennedy SH, O'Donovan C, et al.. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 5-69.
106. Bushe CJ, Tohen M. Bipolar Disorder and Safety Monitoring for Clinicians: A Review of the Evidence and the Implications. In: Yatham LN, Maj M, eds. Bipolar Disorder: Clinical and Neurolobiological Foundations. Chichester: Wiley, 2010.
107. Ng F, Mammen OK, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; 11: 559-595.
108. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord 2009; 117 (Suppl. 1): 1-2.
109. National Institute for Health and Clinical Excellence. Bipolar Disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. ; last accessed November 28, 2011.
110. Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005; 7: 307-325.
111. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006; 8: 232-241.
112. Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study. Psychiatry Res 2011; 190: 110-114.
113. Sussman N. General Principles of Psychopharmacology. in: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 9th ed. Philadelphia: Lippincott, Williams & Wilkins, 2009.
114. Liauw SS, McIntyre RS. Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother 2010; 11: 2827-2837.
115. National Health and Medical Research Council. A Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. ; last accessed November 28, 2011.
116. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721-739.
117. Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 2011; 25: 289-298.
118. Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. Bipolar Disord 2011; 13: 219-226.
119. Hirschfeld RMA, Bowden CL, Gitlin MJ et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
120. Semple D, Smyth R. Depressive Illness Oxford Handbook of Psychiatry, 2nd ed. New York: Oxford University Press, 2009.
121. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72: 156-167.
122. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239.
123. Post RM, Altshuler LL, Leverich GS et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189: 124-131.
124. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537-1547.
125. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol 2010; 30: 306-311.
126. Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res 2010; 44: 8-14.
127. Kemp DE, Ganocy SJ, Brecher M et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 2011; 130: 171-179.
128. Phelps J. Tapering antidepressants: is 3months slow enough? Med Hypotheses 2011; 77: 1006-1008.
129. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
130. Gillhoff K, Gaab J, Emini L, Maroni C, Tholuck J, Greil W. Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. Prim Care Companion J Clin Psychiatry 2010; 12: PCC. 09m00906.
131. Benazzi F. Is depressive mixed state a transition between depression and hypomania? Eur Arch Psychiatry Clin Neurosci 2004; 254: 69-75.
132. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000; 12: 5-10.
133. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003; 13: 57-66.
134. Calabrese JR, Keck PE, Jr, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21: 340-342.
135. Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263-1271.
136. Bobo WV, Shelton RC. Risperidone long-acting injectable (Risperdal Consta) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother 2010; 10: 1637-1658.
137. Popovic D, Reinares M, Amann B et al. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 2011; 213: 657-667.
138. Green AI, Tohen M, Patel JK et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157: 982-986.
139. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62: 818-825.
140. Tohen M, Chengappa KNR, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345.
141. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263.
142. Vieta E, T'joen C, McQuade RD et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165: 1316-1325.
143. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010; 26: 1485-1496.
144. Juruena MF, Ottoni GL, Machado-Vieira R et al. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 94-99.
145. Weisler RH, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania: a randomized, double-blind placebo-controlled trial. Presented at the 2003 Institute on Psychiatric Services Meeting, October 29-November 2, 2003, Boston, MA, USA.
146. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130-137.
147. Chang JS, Ha K-S, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67: 461-467.
148. Redmond JR, Jamison KL, Bowden CL. Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series. CNS Spectr 2006; 11: 915-918.
149. Corya SA, Perlis RH, Keck PE et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006; 67: 798-806.
150. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374-1382.